方盛製藥(603998.SH):三花接骨散及健胃愈瘍顆粒持有人變更後及原料藥伊班膦酸鈉通過藥品GMP符合性檢查
格隆匯12月9日丨方盛製藥(603998.SH)公佈,近日,湖南方盛製藥股份有限公司收到湖南省藥品監督管理局簽發的《藥品GMP符合性檢查結果通知書》,公司三花接骨散及健胃愈瘍顆粒持有人變更後及原料藥伊班膦酸鈉通過現場檢查(即藥品GMP符合性檢查)。
此次通過GMP符合性檢查為原料藥(伊班膦酸鈉);三花接骨散(國藥準字Z10950013)及健胃愈瘍顆粒(國藥準字Z10960018)持有人變更後藥品GMP符合性檢查。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.